Rosnilimab acts as an agonist to stimulate PD-1, killing those cells with high PD-1 expression and pushing others into an ...

Individuals diagnosed with chronic spontaneous urticaria (CSU) are at a moderately increased risk of multiple cardiovascular ...

Sonoma Biotherapeutics has announced positive interim results from its ongoing phase 1 Regulate-RA trial evaluating ...

Perimenopause was linked to higher PsA disease activity and greater tender/swollen joint counts when compared with the pre- ...

Sonoma Biotherapeutics, Inc., a clinical-stage biotechnology company developing engineered regulatory T cell (Treg) therapies for autoimmune and inflammatory diseases, today announced interim safety ...

The Global Sepsis Diagnostics Market size, valued at USD 1,133.2 million in 2018, grew substantially to USD 1,790.9 million ...

Aldeyra Therapeutics reports positive results from phase 2 clinical trial in alcohol-connected hepatitis: Lexington, Massachusetts Thursday, October 30, 2025, 17:30 Hrs [IST] Alde ...

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative ...

Objective To investigate the association between peripheral disease activity and pre-eclampsia, gestational hypertension, ...

A recent study published in the journal of Egyptian Rheumatology and Rehabilitation revealed that children with psoriasis are ...

Glucagon-like peptide 1 receptor agonists (GLP-1RA) have made waves as treatments for obesity and type 2 diabetes, but a new report suggests they might also have clinical benefits for certain patients ...

Objective: To describe the joint manifestations associated with clonal haematopoiesis and to compare patients with and ...